1. Haemonetics will publish Q2 FY 2026 results on November 6, 2025. 2. A conference call for investors is scheduled for the same day. 3. Haemonetics focuses on medical technology improving healthcare efficiency.
The scheduled earnings report can lead to improved investor sentiment if results meet or exceed expectations, similar to past performance spikes occurring during earnings announcements.
The investor call and earnings results directly relate to investor interest and potential shifts in stock price based on reported financial health.
The immediate impact will likely be felt around the earnings announcement date, similar to previous quarterly results impacting stock prices significantly.
BOSTON, Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, November 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 6, 2025.
The call can be accessed via teleconference at: Q2 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/6q36mw7d
A replay of the conference call and webcast will be available for one year beginning on November 6, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-second-quarter-fiscal-year-2026-results-november-6-2025-302580124.html
SOURCE Haemonetics Corporation